Rónán Mullen (Independent) | Oireachtas source

I understand that and I will be very brief. Is Mr. Flanagan saying that legislation would be needed to activate the OMP assessment pathway envisaged in the 2014 national rare disease plan? If not, are there any remaining obstacles? Is there unfinished work set out in the plan that ought to have been completed by now? Were Ireland to match Germany in the provision of orphan medicines at the same price currently paid by the Germans, do the witnesses have an estimate as to how much that might cost?